Quick Answer
VACCINEX, INC. reported Total Revenue of $601.0 thousand for the year ending 2024.
- VACCINEX, INC. showed an increase of +5.4% in Total Revenue from 2023 to 2024.
- This data is from VACCINEX, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $206.0 thousand | Q2 2018: $126.0 thousand | Q3 2018: $198.0 thousand | Q1 2019: $94.0 thousand | Q2 2019: $25.0 thousand | Q3 2019: $404.0 thousand | Q3 2020: $625.0 thousand | Q1 2021: $850.0 thousand | Q3 2021: $50.0 thousand | Q3 2022: $50.0 thousand | Q1 2023: $550.0 thousand | Q3 2023: $20.0 thousand | Q1 2024: $104.0 thousand | Q2 2024: $232.0 thousand | Q3 2024: $52.0 thousand.
- Over the full 8 years of available data (2017 to 2024), VACCINEX, INC.'s Total Revenue has grown by 567.8%.
- Historical annual values: Fiscal year 2024: $601.0 thousand | Fiscal year 2023: $570.0 thousand | Fiscal year 2022: $275.0 thousand | Fiscal year 2021: $900.0 thousand | Fiscal year 2020: $625.0 thousand | Fiscal year 2019: $523.0 thousand | Fiscal year 2018: $724.0 thousand | Fiscal year 2017: $90.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: